Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
I-Mab (NASDAQ:IMAB – Get Rating) – Analysts at Jefferies Financial Group cut their FY2022 earnings per share estimates for I-Mab in a research note issued on Wednesday, March 30th. Jefferies Financial Group analyst K. Shi now expects that the company will post earnings per share of ($3.45) for the year, down from their prior estimate […]
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab,...
National Bank of Canada FI bought a new position in I-Mab (NASDAQ:IMAB – Get Rating) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 289,300 shares of the company’s stock, valued at approximately $13,710,000. A number of other hedge funds and other institutional investors have also recently […]
I-Mab (NASDAQ:IMAB – Get Rating) and Iterum Therapeutics (NASDAQ:ITRM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations. Risk & Volatility I-Mab has a beta of 0.94, indicating […]